X Genomics Inc (TXG) stock saw a decline, ending the day at $14.9 which represents a decrease of $-1.41 or -8.65% from the prior close of $16.31. The stock opened at $16.1 and touched a low of $14.19 ...

Analysts have set 12-month price targets for 10x Genomics, revealing an average target of $19.67, a high estimate of $28.00, ...

Weiss Ratings reaffirmed their sell (e+) rating on shares of 10x Genomics (NASDAQ:TXG – Free Report) in a report released on Saturday,Weiss Ratings reports. TXG has been the subject of several other ...

Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced preliminary, unaudited select ...

Leerink Partners analyst Puneet Souda has maintained their bullish stance on TXG stock, giving a Buy rating on January 13.Stay Ahead of the ...

10x Genomics (TXG – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Ryskin from Bank of America Securities maintained a Hold rating on ...

Genomics is innovating in spatial technologies but faces hurdles. Discover why TXG stock’s price/cashflow ratio and competition warrant a Sell rating.

X Genomics Inc (TXG) stock saw a decline, ending the day at $14.98 which represents a decrease of $-0.46 or -2.98% from the prior close of $15.44. The stock opened at $16.11 and touched a low of ...

"Our team delivered solid sequential revenue growth over last quarter," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "We are confident the work we've done throughout 2024 sets us up ...

Shares of 10X Genomics (NASDAQ:TXG) climbed 7% as the company reported preliminary fourth-quarter sales that surpassed analyst expectations. The life sciences company, known for its work in single ...